U.S. Markets open in 7 hrs 19 mins
  • S&P Futures

    3,240.50
    -61.75 (-1.87%)
     
  • Dow Futures

    26,102.00
    -455.00 (-1.71%)
     
  • Nasdaq Futures

    11,079.50
    -263.25 (-2.32%)
     
  • Russell 2000 Futures

    1,530.60
    -27.80 (-1.78%)
     
  • Crude Oil

    35.51
    -0.66 (-1.82%)
     
  • Gold

    1,869.10
    +1.10 (+0.06%)
     
  • Silver

    23.35
    -0.01 (-0.02%)
     
  • EUR/USD

    1.1686
    +0.0008 (+0.0701%)
     
  • 10-Yr Bond

    0.8350
    0.0000 (0.00%)
     
  • Vix

    37.59
    -2.69 (-6.68%)
     
  • GBP/USD

    1.2909
    -0.0015 (-0.1136%)
     
  • USD/JPY

    104.1750
    -0.4350 (-0.4158%)
     
  • BTC-USD

    13,171.72
    -315.51 (-2.34%)
     
  • CMC Crypto 200

    258.54
    +15.87 (+6.54%)
     
  • FTSE 100

    5,581.75
    -1.05 (-0.02%)
     
  • Nikkei 225

    22,991.69
    -340.25 (-1.46%)
     

Successful Remote Installation of TRUFORMA™

·4 mins read

Permits Validation and Pilot Program Progress During COVID-19 Restrictions

ANN ARBOR, Mich., July 21, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company, announced today that, in response to the COVID-19 crisis, it successfully implemented its first completely remote installations of TRUFORMA™, the Company's inaugural point-of-care diagnostic device. Remote installation has enabled Zomedica to proceed with validation testing with its clinical College of Veterinary Medicine partners at Auburn, Mississippi State, and Purdue Universities.

TRUFORMA’s straightforward design and intuitive user experience facilitates entirely remote installation of the device and subsequent virtual operational training of the TRUFORMA platform. Validation testing and a planned pilot program are not expected to be delayed by any social distancing mandates.

Zomedica also recently completed verification of canine cortisol for use with its TRUFORMA platform, and will be adding that assay to its ongoing validation studies, which already include canine and feline total T4 (“tT4”) and canine and feline TSH (thyroid stimulating hormone) assays. The Company intends to continue to add additional assays to its expanding TRUFORMA platform.

“We remain tightly focused on bringing TRUFORMA™ to the veterinary point-of-care market at the earliest possible time,” said Robert Cohen, Zomedica Interim Chief Executive Officer. “During the several weeks since I joined the Company, I have been impressed by the breadth, depth, and utility of our TRUFORMA technology, as well as the capabilities and dedication to companion animal care by our employees and external partners."

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Reader Advisory

Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to Zomedica’s expectations regarding the public offering. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon Zomedica’s business operations generally, including Zomedica’s ability to develop its diagnostic products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
PCG Advisory Group
Kirin Smith, COO
ksmith@pcgadvisory.com
+1 646.863.6519

Media Contact:
Meredith Newman
mnewman@zomedica.com
+1 734.369.2555 ext. 119

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7d3f3477-fd8f-4899-87e0-da96ccba95ee